Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors

US11384076B2 · kind B2 · utility

Assignees

• Universität Regensburg · DE
• Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Siavosh Mahboobi · Regensburg, DE
• Andreas Sellmer · Lappersdorf, DE
• Herwig Pongratz · Regensburg, DE
• Bernardette Pilsl · Wenzenbach, DE
• Oliver Krämer · Nackenheim, DE
• Thomas Kindler · Mainz, DE
• Mandy Beyer · Wiesbaden, DE

Key dates

• Filing date: Aug 9, 2018
• Grant date: Jul 12, 2022
• Expiry date: Oct 21, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.